Table 2.

Annualised relapse rates (ARR) [95% CI]

	ARR [95% CI]
Cohort	Before treatment	During treatment	After cessation
All (n = 685)	1.71 [1.59, 1.85]	0.50 [0.44, 0.55]	0.43 [0.38, 0.49]
Switch to new therapy (12 months)
None (n = 92)	1.38 [1.09, 1.73]	0.28 [0.17, 0.42]	0.26 [0.16, 0.36]
Low efficacy (n = 184)	1.38 [1.17, 1.60]	0.33 [0.24, 0.41]	0.51 [0.40, 0.62]
High efficacy (n = 409)	1.95 [1.79, 2.13]	0.62 [0.54, 0.69]	0.44 [0.36, 0.51]
Time to switch (months)
0–2 (n = 322)	1.87 [1.68, 2.07]	0.58 [0.50, 0.67]	0.38 [0.27, 0.42]
2–4 (n = 108)	1.72 [1.43, 2.03]	0.52 [0.39, 0.67]	0.53 [0.41, 0.65]
4–6 (n = 48)	1.21 [0.81, 1.68]	0.29 [0.13, 0.48]	0.71 [0.46, 0.98]
6–8 (n = 25)	1.72 [0.96, 2.64]	0.44 [0.16, 0.84]	0.80 [0.44, 1.37]
8–10 (n = 19)	1.74 [1.11, 2.32]	0.32 [0.11, 0.58]	0.84 [0.32, 1.68]
10–12 (n = 22)	1.23 [0.64, 2.18]	0.23 [0.05, 0.36]	0.86 [0.45, 1.41]
12+ (n = 141)	1.60 [1.35, 1.88]	0.42 [0.31, 0.54]	0.28 [0.20, 0.38]

ARRs were computed as the total number of relapses observed over the specific 12-month period divided by the number of patients. ‘Switch to new therapy’ shows the ARRs stratified by the efficacy of the new therapy commenced within 12 months of fingolimod cessation. ‘Time to switch’ shows the ARRs stratified by the time to commencement of any new therapy following fingolimod cessation